Case study – Combination matrix to determine Bliss independence synergy scoresOncolines®2024-11-19T11:39:02+01:00
Combination matrix to determine Bliss independence synergy scores
Combining two drugs that act on different targets is a cornerstone of cancer therapy. Combination therapy can produce a more effective treatment response in less cycles, and therefore reduces the incidence of drug resistance.
Several combination therapies are approved by the FDA for the treatment of cancer, among which the combination of MEK inhibitors and B-RAF inhibitors in advanced melanoma.
The combination of the selective MEK inhibitor binimetinib and the selective B-RAF inhibitor encorafenib showed synergistic effects at low concentrations of both drugs in a melanoma cell line.
Oncolines uses a 6 by 6 combination matrix to determine synergistic effects. Synergy scores are calculated using the Bliss independence model.
Figure 1: Combination matrix of the selective MEK inhibitor binimetinib and the selective B-RAF inhibitor encorafenib in B-RAF-mutant melanoma cell line G-361.
